Lundbeck Says Data Supports H2 Anti-Depressant Filing

Danish drugmaker Lundbeck said on Monday that the results of Phase III trials for an antidepressant drug candidate have given it the basis to apply for approval in the United States, Europe and Canada in the second half of 2012.
Reuters